Advertisement

Pharmacy World and Science

, Volume 24, Issue 5, pp 177–181 | Cite as

Measuring the impact of medicines information services on patient care: methodological considerations

  • Anne SpinewineEmail author
  • Bryony Dean
Article

Abstract

Introduction: Medicines information services (MISs) aim to promote the safe, effective and economic use of medicines. Results from published studies suggest that they provide effective information, which in many cases results in improved patient outcome. However, there are several methodological issues that are important in the interpretation of such studies.Aim: To address methodological issues in the evaluation of MISsObjectives: To carry out a critical appraisal of papers assessing the impact on patient outcome of passive information given to health care professionals, to identify the key methodological issues and to make recommendations for future research in Europe. Methods: Literature search to identify relevant papers meeting the inclusion criteria, critical evaluation of the methods usedResults: Most studies have been conducted in the United States. Various methodological considerations were identified: study design, sampling, data collection, choice of outcome measures, and validity. The results of each study are interpreted in view of the methods used. In addition, the implications of the methods selected on the validity, reliability and generalisability of the results are discussed. Finally, suggestions for future studies are provided, in order to maximise validity and reliability.

Drug information Health care professionals Impact Medicines information Passive information Patient outcome Pharmacy service Review 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg JM, Fuentes RJ, Starr CH, Kirschenbaum HL, McGuire H. Pharmacist-operated drug information centers in the United States. Am J Health Syst Pharm 1995; 52: 991–6.PubMedGoogle Scholar
  2. 2.
    Calder G, Davies JS, McNulty H, Smith JC. Drug information network in the United Kingdom National Health Service. Am J Hosp Pharm 1981; 38: 663–6.PubMedGoogle Scholar
  3. 3.
    Cotter SM, Barber ND, McKee M. Survey of clinical pharmacy services in United Kingdom National Health Service hospitals. Am J Hosp Pharm 1994; 51: 2676–84.PubMedGoogle Scholar
  4. 4.
    Delaney T. EAHP survey of hospital-based pharmaceutical services in Europe-1995. Eur Hosp Pharm 1996; 2: 92–105.Google Scholar
  5. 5.
    George CF, Waters WE, Nicholas JA. Prescription information leaflets: a pilot study in general practice. Br Med J (Clin Res Ed) 1983; 287: 1193–6.Google Scholar
  6. 6.
    Gibbs S, Waters WE, George CF. The benefits of prescription information leaflets (1). Br J Clin Pharmacol 1989; 27: 723–39.PubMedGoogle Scholar
  7. 7.
    Gibbs S, Waters WE, George CF. Prescription information leaflets: a national survey. J R Soc Med 1990; 83: 292–7.PubMedGoogle Scholar
  8. 8.
    Denig P, Haaijer-Ruskamp FM, Zijsling DH. Impact of a drug bulletin on the knowledge, perception of drug utility, and prescribing behavior of physicians. DICP 1990; 24: 87–93.PubMedGoogle Scholar
  9. 9.
    Lyrvall H, Nordin C, Jonsson E, Alvan G, Ohman B. Potential savings of consulting a drug information center. Ann Pharmacother 1993; 27: 1540.Google Scholar
  10. 10.
    Pearson RE, Lauper RD, Davis LJ. Experience with a drug information services review committee. Am J Hosp Pharm 1975; 32: 31–4.PubMedGoogle Scholar
  11. 11.
    Cardoni AA, Thompson TJ. Impact of drug information services on patient care. Am J Hosp Pharm 1978; 35: 1233–7.PubMedGoogle Scholar
  12. 12.
    Baker RP, Gallo GR. Drug information services: how health care professionals use the information provided. J Clin Hosp Pharm 1984; 9: 133–8.PubMedGoogle Scholar
  13. 13.
    Repchinsky CA, Masuhara EJ. Quality assurance program for a drug information center. Drug Intell Clin Pharm 1987; 21: 816–20.PubMedGoogle Scholar
  14. 14.
    Golightly LK, Davis AG, Budwitz WJ, Gelman CJ, Rathmann KL, Sutherland EW, Rumack BH. Documenting the activity and effectiveness of a regional drug information center. Am J Hosp Pharm 1988; 45: 356–61.PubMedGoogle Scholar
  15. 15.
    Moody ML. Revising a drug information center quality assurance program to conform to Joint Commission standards. Am J Hosp Pharm 1990; 47: 792–4.PubMedGoogle Scholar
  16. 16.
    Stubbington C, Bowey J, Hands D, Brown D. Drug information replies to queries involving adverse events: impact on clinical practice. Hosp Pharm 1998; 5: 81–4.Google Scholar
  17. 17.
    Melnyk PS, Shevchuk YM, Remillard AJ. Impact of the dial access drug information service on patient outcome. Ann Pharmacother 2000; 34: 585–92.PubMedGoogle Scholar
  18. 18.
    Shah, R, Duggan, C, Tugwell, C. Developing ways to assess the impact of drug information on patient care. 11th International Social Pharmacy Workshop, June 13–17, Kupio, Finland, 2000.Google Scholar
  19. 19.
    Amerson AB, Wallingford DM. Twenty years' experience with drug information centers. Am J Hosp Pharm 1983; 40: 1172–8.PubMedGoogle Scholar
  20. 20.
    Dawson P. The impact of drug information services on drug use. Br J Pharm Pract 1983; 5: 10–5.Google Scholar
  21. 21.
    Pearson RE, Schmalgemeier W, Bendall M, Mehta P. Michigan regional drug information network. 3. Utilization of information received from a drug information center. Am J Hosp Pharm 1972; 29: 229–34.PubMedGoogle Scholar
  22. 22.
    Donabedian A. The quality of care. How can it be assessed? JAMA 1988; 260: 1743–8.PubMedGoogle Scholar
  23. 23.
    Johnson RE, Campbell WH, Christensen DB. Quality assurance of pharmaceutical services in hospitals. Am J Hosp Pharm 1974; 31: 640–7.PubMedGoogle Scholar
  24. 24.
    Stolar MH. Quality assurance of pharmaceutical services: an objective-based planning strategy. Am J Hosp Pharm 1981; 38: 209–12.PubMedGoogle Scholar
  25. 25.
    Smith F. Qualitative interviews. Int J Pharm Pract 1998; 6: 97–108.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  1. 1.Cellular and Molecular PharmacologyUniversit, Catholique de LouvainBrusselsBelgium
  2. 2.Academic Pharmacy Unit, Hammersmith Hospitals NHS Trust and the School of PharmacyUniversity of LondonUK

Personalised recommendations